Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Midi Health is a direct-to-consumer telehealth platform that specializes in GLP-1 receptor agonist prescriptions for weight management and metabolic health. The platform connects patients with licensed physicians via digital consultations, aiming to simplify access to medications like semaglutide and tirzepatide. Midi Health reports serving thousands of patients nationwide, with emphasis on rapid onboarding and medication delivery.
Understanding how Midi Health operates—and what clinical evidence supports telehealth GLP-1 prescribing—matters as compounded and branded options proliferate. While Midi Health offers convenience, questions remain about dosing personalization, genetic predisposition screening, and whether one-size telehealth protocols match individual metabolic profiles. This article evaluates Midi Health's model against clinical evidence and introduces how genetic insight may enhance GLP-1 selection conversations.
What Is Midi Health and How Does It Work?
Midi Health operates as a membership-based telehealth service focused on GLP-1 therapy. Patients complete a health questionnaire, consult with a physician online, and receive a prescription shipped directly to their home. Midi Health emphasizes speed and accessibility, with many consultations completed within days.
The platform primarily prescribes branded semaglutide (Wegovy) and tirzepatide (Zepbound, Mounjaro) through traditional pharmaceutical supply chains. Midi Health's model relies on standardized dosing protocols—patients typically start at the lowest dose and titrate weekly. The clinical appeal centers on removing geographic barriers to GLP-1 access, though personalization depth varies by provider availability.
Clinical Evidence on Telehealth GLP-1 Prescribing Models
Telehealth GLP-1 delivery has grown rapidly, with observational data supporting remote consultations as effective for patient access. Studies show that online GLP-1 initiation yields weight loss and metabolic improvements comparable to in-person care when physician oversight is present. However, research on outcome differences between telehealth platforms remains limited; most evidence compares telehealth versus no treatment, not telehealth versus specialized compounding models.
Midi Health's published outcomes data focuses on patient retention and satisfaction rather than biomarker-level response prediction. Clinical literature suggests that GLP-1 efficacy varies significantly by individual genetic factors, baseline insulin sensitivity, and gastrointestinal tolerance—variables not typically assessed in standardized telehealth protocols. This variability underscores why some providers now recommend genetic screening before GLP-1 selection.
| Factor |
Midi Health Model |
Compounded + Genetic Approach |
Clinical Relevance |
| Prescribing Speed |
1-3 days |
2-5 days (includes testing) |
Faster initiation may improve compliance; delays acceptable for genetic insight. |
| Dosing Personalization |
Standardized titration |
Provider-guided + genetic context |
Genetic predispositions (GLP1R, GIPR variants) may inform initial dose strategy. |
| Medication Type |
Branded semaglutide/tirzepatide |
Compounded semaglutide/tirzepatide |
Bioavailability similar; compounding may offer cost flexibility and microdose options. |
| Provider Consultation |
Licensed physician online |
Licensed provider + genetic counseling |
Genetic test results support deeper personalization discussion beyond standard protocols. |
Midi Health's Approach to Patient Screening and Safety
Midi Health screens patients for contraindications via medical questionnaire, including personal or family history of thyroid cancer and pancreatitis risk factors. Physicians review responses and determine eligibility before prescribing. This process protects patient safety but relies on patient-reported history accuracy and does not include objective biomarker assessment or genetic evaluation.
Standard telehealth screening typically assesses weight, BMI, and baseline comorbidities. Midi Health does not routinely measure insulin resistance, lipid profiles, or fasting glucose—data that can predict GLP-1 response patterns. Additionally, genetic variants affecting GLP-1 receptor sensitivity are not evaluated in standard Midi Health consultations, meaning two patients with identical BMI may have fundamentally different metabolic needs.
How Genetic Testing Refines GLP-1 Selection Beyond Telehealth Protocols
Genetic predispositions in peptide receptor pathways—such as GLP1R rs6923761 and GIPR rs1800437 variants—may influence how individual bodies respond to GLP-1 therapy. These genetic factors affect receptor signaling, satiety hormone response, and weight loss trajectory. A genetic test can reveal these predispositions, supporting providers in tailoring initial dosing strategy and medication selection for each patient.
PlexusDx's Precision Peptide Genetic Test evaluates key variants in GLP-1 and GIP receptor pathways, as well as metabolic genes like FTO and MC4R. Results do not predict exact medication response—genetics is one input among many—but may help a provider and patient have a more informed conversation about which GLP-1 agent or dosing approach aligns with the patient's genetic profile. This level of personalization extends beyond what standard Midi Health consultations provide.
Comparing Midi Health to Compounded GLP-1 Partnerships
Midi Health and compounded GLP-1 providers serve different market needs. Midi Health excels at rapid access and brand-name prescribing; compounded pharmacies offer dose flexibility, potentially lower cost, and the ability to work with providers who use genetic insights. Both models are legitimate; the choice depends on patient priorities—speed and brand assurance versus personalization and cost optimization.
Compounded semaglutide and tirzepatide from licensed 503A pharmacies are not FDA-approved as finished medications but are prepared under state pharmacy boards and federal USP standards. They offer clinical equivalence to branded versions at variable dosing strengths. When paired with genetic testing and provider-guided protocols, compounding allows for microdose initiation or fine-tuning that may reduce side-effect burden while maintaining efficacy.
Safety, Side Effects, and Clinical Monitoring Across Platforms
GLP-1 safety profile is well-established: nausea, constipation, and gastrointestinal upset are common early side effects, while rare pancreatitis and thyroid concerns require screening. Midi Health and compounded providers both screen for contraindications, but ongoing monitoring depth varies. Midi Health typically offers email support and brief follow-ups; specialty compounding practices often provide more frequent clinical touchpoints and dosing adjustments based on patient feedback.
Patients starting GLP-1—whether through Midi Health or compounded sources—should expect titration protocols lasting 4–20 weeks. Genetic insights into GLP-1 receptor variants may help providers anticipate which patients are likely to experience milder or more pronounced side effects, enabling proactive counseling and dose adjustment strategies. This personalized approach can improve tolerability and long-term adherence.
How PlexusDx Supports a More Personalized Approach
PlexusDx partners with patients and providers to move beyond standardized telehealth protocols. By integrating the Precision Peptide Genetic Test—which evaluates GLP1R, GIPR, FTO, and MC4R variants—patients gain context about their genetic predispositions in peptide signaling pathways. This information, interpreted by a qualified healthcare provider, may support more thoughtful conversations about which GLP-1 agent, initial dose, and titration pace aligns with individual biology.
The Precision Peptide Genetic Test costs $99 as an add-on or $298 as a standalone assessment. Results reveal predispositions—not guarantees—in key genetic pathways affecting GLP-1 response. Combined with compounded semaglutide (from $179/month) or tirzepatide (from $229/month), genetic insight enables providers to craft truly personalized protocols rather than apply population-level dosing templates to every patient.
Whether a patient chooses Midi Health, a traditional provider, or a compounded pharmacy, genetic testing can enhance the clinical conversation. PlexusDx positions genetic insight as a tool for provider-patient collaboration, helping clarify who may benefit from lower starting doses, extended titration, or alternative GLP-1 agents based on underlying metabolic and genetic context.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Midi Health a legitimate telehealth GLP-1 service?
Yes, Midi Health is a licensed telehealth platform connecting patients with physicians for GLP-1 prescriptions. Physicians conduct consultations and issue legitimate prescriptions for semaglutide and tirzepatide. However, the level of personalization and biomarker assessment varies by provider.
What medications does Midi Health prescribe, and how do they differ from compounded options?
Midi Health prescribes branded semaglutide (Wegovy) and tirzepatide (Zepbound, Mounjaro) through standard pharmaceutical channels. Compounded semaglutide and tirzepatide offer similar active ingredients but with dose flexibility and potentially lower cost. Both are clinically valid; choice depends on access, cost, and personalization preferences.
Does Midi Health include genetic testing in its screening process?
Midi Health does not routinely include genetic screening. PlexusDx's Precision Peptide Genetic Test evaluates GLP1R and GIPR variants that may influence response patterns, providing context for more personalized provider conversations alongside compounded medications.
What are the safety considerations when choosing between Midi Health and compounded GLP-1?
Both models screen for contraindications and monitor side effects. Compounded providers paired with genetic testing may enable earlier dose adjustment based on genetic predispositions, potentially improving tolerability. Ongoing medical supervision is essential with either approach.
How can genetic testing improve my GLP-1 therapy experience?
Genetic testing reveals predispositions in peptide pathways that may influence GLP-1 effectiveness and side effects. Results should be interpreted with a qualified provider to inform medication selection, starting dose, and titration pace—supporting a more individualized approach than one-size protocols offer.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Orderly Meds Review: How Genetic Profiling Shapes GLP-1 Selection
Midi Health Review: GLP-1 Selection and Genetic Biomarker Context